Subjects -> MEDICAL SCIENCES (Total: 8690 journals)
    - ANAESTHESIOLOGY (121 journals)
    - CARDIOVASCULAR DISEASES (338 journals)
    - DENTISTRY (294 journals)
    - ENDOCRINOLOGY (151 journals)
    - FORENSIC SCIENCES (42 journals)
    - HEMATOLOGY (158 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (178 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2415 journals)
    - NURSES AND NURSING (370 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (386 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (275 journals)
    - PSYCHIATRY AND NEUROLOGY (833 journals)
    - RESPIRATORY DISEASES (105 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (406 journals)

RESPIRATORY DISEASES (105 journals)                     

Showing 1 - 105 of 105 Journals sorted alphabetically
Advances in Respiratory Medicine     Open Access   (Followers: 7)
Advances in Thoracic Diseases     Open Access   (Followers: 2)
American Journal of Respiratory and Critical Care Medicine     Full-text available via subscription   (Followers: 273)
American Journal of Respiratory Cell and Molecular Biology     Full-text available via subscription   (Followers: 22)
American Review of Respiratory Disease     Full-text available via subscription   (Followers: 4)
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Annals of the American Thoracic Society     Full-text available via subscription   (Followers: 18)
Annals of Thoracic Medicine     Open Access   (Followers: 6)
Archives of Pulmonology and Respiratory Care     Open Access   (Followers: 2)
Archivos de Bronconeumología     Full-text available via subscription  
Archivos de Bronconeumología (English Edition)     Full-text available via subscription   (Followers: 1)
Asthma Research and Practice     Open Access   (Followers: 2)
BMC Pulmonary Medicine     Open Access   (Followers: 7)
BMJ Open Respiratory Research     Open Access   (Followers: 8)
Breathe     Open Access   (Followers: 7)
Canadian Journal of Respiratory Therapy     Full-text available via subscription   (Followers: 3)
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine     Hybrid Journal   (Followers: 1)
Canadian Respiratory Journal     Open Access   (Followers: 3)
Case Reports in Pulmonology     Open Access   (Followers: 3)
Chest     Full-text available via subscription   (Followers: 109)
Chest Disease Reports     Open Access   (Followers: 2)
Chronic Respiratory Disease     Hybrid Journal   (Followers: 9)
Clinical Lung Cancer     Hybrid Journal   (Followers: 6)
Clinical Medicine Insights : Circulatory, Respiratory and Pulmonary Medicine     Open Access   (Followers: 3)
Clinical Pulmonary Medicine     Hybrid Journal   (Followers: 3)
COPD Research and Practice     Open Access   (Followers: 1)
COPD: Journal of Chronic Obstructive Pulmonary Disease     Hybrid Journal   (Followers: 17)
Current Opinion in Pulmonary Medicine     Hybrid Journal   (Followers: 10)
Current Pulmonology Reports     Hybrid Journal  
Current Research in Tuberculosis     Open Access   (Followers: 3)
Current Respiratory Care Reports     Hybrid Journal   (Followers: 2)
Current Respiratory Medicine Reviews     Hybrid Journal   (Followers: 5)
Der Pneumologe     Hybrid Journal   (Followers: 1)
Egyptian Journal of Chest Diseases and Tuberculosis     Open Access   (Followers: 3)
ERJ Open Research     Open Access   (Followers: 5)
Eurasian Journal of Pulmonology     Open Access  
European Clinical Respiratory Journal     Open Access   (Followers: 4)
European Respiratory Journal     Full-text available via subscription   (Followers: 42)
European Respiratory Review     Open Access   (Followers: 10)
Experimental Lung Research     Hybrid Journal   (Followers: 1)
Expert Review of Respiratory Medicine     Hybrid Journal   (Followers: 5)
Heart & Lung: The Journal of Acute and Critical Care     Hybrid Journal   (Followers: 14)
Heart, Lung and Circulation     Full-text available via subscription   (Followers: 9)
Indian Journal of Respiratory Care     Open Access   (Followers: 3)
Indian Journal of Tuberculosis     Full-text available via subscription  
Influenza and Other Respiratory Viruses     Open Access   (Followers: 3)
International Journal of Chronic Obstructive Pulmonary Disease     Open Access   (Followers: 3)
Journal of Association of Chest Physicians     Open Access   (Followers: 2)
Journal of Asthma     Hybrid Journal   (Followers: 5)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 5)
Journal of Bronchology & Interventional Pulmonology     Hybrid Journal   (Followers: 5)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases     Open Access  
Journal of Heart and Lung Transplantation     Hybrid Journal   (Followers: 12)
Journal of Respiratory Medicine     Open Access   (Followers: 5)
Journal of Respiratory Research     Open Access   (Followers: 3)
Journal of Tuberculosis Research     Open Access   (Followers: 1)
Jurnal Respirasi     Open Access  
Karger Kompass Pneumologie     Full-text available via subscription   (Followers: 1)
Kindheit und Entwicklung     Hybrid Journal  
Lung     Hybrid Journal   (Followers: 3)
Lung Cancer     Hybrid Journal   (Followers: 15)
Lung Cancer International     Open Access   (Followers: 2)
Lung Cancer: Targets and Therapy     Open Access   (Followers: 3)
Lung India     Open Access   (Followers: 1)
Multidisciplinary Respiratory Medicine     Open Access   (Followers: 4)
npj Primary Care Respiratory Medicine     Open Access   (Followers: 2)
Open Journal of Respiratory Diseases     Open Access   (Followers: 2)
Open Respiratory Medicine Journal     Open Access   (Followers: 2)
Paediatric Respiratory Reviews     Hybrid Journal   (Followers: 11)
Pediatric Quality & Safety     Open Access  
Pediatric Respirology and Critical Care Medicine     Open Access   (Followers: 1)
Pulmonary Circulation     Open Access   (Followers: 4)
Pulmonary Medicine     Open Access   (Followers: 3)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pulmonary Therapy     Open Access   (Followers: 2)
Pulmonology and Respiratory Research     Open Access   (Followers: 2)
Respiratory Care     Full-text available via subscription   (Followers: 12)
Respiratory Investigation     Full-text available via subscription   (Followers: 1)
Respiratory Medicine     Hybrid Journal   (Followers: 19)
Respiratory Medicine : X     Open Access  
Respiratory Medicine Case Reports     Open Access  
Respiratory Medicine CME     Hybrid Journal  
Respiratory Medicine Extra     Full-text available via subscription   (Followers: 1)
Respiratory Physiology & Neurobiology     Hybrid Journal   (Followers: 4)
Respiratory Research     Open Access   (Followers: 1)
Respirology     Hybrid Journal   (Followers: 5)
Respirology Case Reports     Open Access  
Revista Americana de Medicina Respiratoria     Open Access  
Revista Chilena de Enfermedades Respiratorias     Open Access  
Revista Inspirar     Open Access  
Revista ORL     Open Access  
Revista Portuguesa de Pneumologia     Open Access  
Sarcoidosis Vasculitis and Diffuse Lung Disese     Full-text available via subscription   (Followers: 3)
Seminars in Respiratory and Critical Care Medicine     Hybrid Journal   (Followers: 14)
Sleep Medicine Reviews     Hybrid Journal   (Followers: 18)
The Clinical Respiratory Journal     Hybrid Journal   (Followers: 3)
The International Journal of Tuberculosis and Lung Disease     Full-text available via subscription   (Followers: 9)
The Lancet Respiratory Medicine     Full-text available via subscription   (Followers: 38)
Therapeutic Advances in Chronic Disease     Open Access   (Followers: 8)
Therapeutic Advances in Respiratory Disease     Open Access   (Followers: 1)
Thorax     Hybrid Journal   (Followers: 39)
Translational Respiratory Medicine     Open Access   (Followers: 1)
Tuberculosis     Hybrid Journal   (Followers: 12)
Tuberculosis Research and Treatment     Open Access   (Followers: 3)
Пульмонология     Full-text available via subscription  


Similar Journals
Journal Cover
Chronic Respiratory Disease
Journal Prestige (SJR): 0.808
Citation Impact (citeScore): 2
Number of Followers: 9  
Hybrid Journal Hybrid journal   * Containing 10 Open Access Open Access article(s) in this issue *
ISSN (Print) 1479-9723 - ISSN (Online) 1479-9731
Published by Sage Publications Homepage  [1092 journals]
  • Serum cystatin C: A potential predictor for hospital-acquired acute kidney
           injury in patients with acute exacerbation of COPD
    • Authors: Dawei Chen, Changchun Cao, Linglin Jiang, Yan Tan, Hongbo Yuan, Binbin Pan, Mengqing Ma, Hao Zhang, Xin Wan
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Hospital-acquired acute kidney injury (HA-AKI) is associated with poor prognosis. In this study, we evaluated whether serum cystatin C on admission could predict AKI in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The retrospective study was conducted using data on adult inpatients with AECOPD from January 2014 to January 2017. A total of 1035 patients were included, among which 79 (7.6%) with HA-AKI were identified. Univariate and multivariate logistic regression analyses were used to investigate predictors of HA-AKI in patients with AECOPD. HA-AKI was associated with poor prognosis, and patients with HA-AKI had higher inpatient mortality (34.2% vs. 2.6%, p < 0.001). Furthermore, after adjusting for confounders, HA-AKI was an independent risk factor for inpatient mortality for patients with AECOPD (odds ratio (OR) 11.02; 95% confidence interval (CI) 4.77–25.45; p < 0.001). Four independent risk factors for HA-AKI (age, levels of urea and cystatin C, and platelet count on admission) were identified in patients with AECOPD. Cystatin C (OR 5.22; 95% CI 2.49–10.95; p < 0.001) was a significant independent predictor of AKI in patients with AECOPD. HA-AKI in patients with AECOPD could be identified with a sensitivity of 73.5% and a specificity of 75.9% (area under the curve (AUC) = 0.803, 95% CI 0.747–0.859) by cystatin C level (cutoff value = 1.3 mg/L) and with a sensitivity of 75.9% and a specificity of 82.0% (AUC = 0.853, 95% CI 0.810–0.896) using a model comprising all significant predictors. Serum cystatin C has the potential for use to predict the risk of HA-AKI in patients with AECOPD.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-09-14T11:12:40Z
      DOI: 10.1177/1479973120940677
      Issue No: Vol. 17 (2020)
  • Correlation between serum bilirubin levels and the severity as well as the
           prognosis of idiopathic pulmonary fibrosis
    • Authors: Shenyun Shi, Yin Liu, Xiaohua Qiu, Min Cao, Yonglong Xiao, Xin Yan
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Bilirubin exerts antioxidant activity that has been associated with respiratory diseases. However, the relationship between serum bilirubin levels and idiopathic pulmonary fibrosis (IPF) is not clear. Therefore, in this study, we evaluated the relationship between serum bilirubin levels and the severity as well as the prognosis of IPF. One hundred and forty-six patients with IPF and 69 healthy individuals as the control group were enrolled as a derivation cohort. Routine blood examination and pulmonary function tests were performed and serum bilirubin levels were measured. To validate the value of serum bilirubin levels to predict the survival of patients with IPF, 40 additional IPF patients were included as a validation cohort. IPF patients were followed-up. Patients with IPF had significantly lower levels of serum total bilirubin (TBIL) and direct bilirubin (DBIL) than those in the control group (P < 0.05). Patients with acute exacerbation of IPF (AE-IPF) had significantly lower levels of serum TBIL and IBIL than those in patients with stable IPF (P < 0.05). The area under the receiver operating characteristic curve (AUROC) of serum TBIL levels for the prediction of the incidence of AE-IPF was 0.72 (95% CI: 0.56–0.87, P = 0.0057). The best cutoff value of serum TBIL level to predict the survival of patients with IPF was 8.8 μmol/l (AUC = 0.75, 95% CI: 0.64–0.87, P = 0.022). The log-rank test showed a significant difference in survival between the two groups (TBIL ≤8.8 μmol/l and TBIL>8.8 μmol/l) in derivation and validation cohort. Cox multiple regression analysis indicated that serum TBIL levels were an independent prognostic factor for IPF prognosis (HR = 0.582, P = 0.026). Serum TBIL levels might be useful for reflecting the severity and predicting the survival of patients with IPF.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-09-10T12:34:25Z
      DOI: 10.1177/1479973120957676
      Issue No: Vol. 17 (2020)
  • Role of community pharmacists in educating asthmatic patients: A
           multi-centered cross-sectional study in Ethiopia
    • Authors: Yohannes Kelifa Emiru, Workineh Woldeselassie Hammeso, Eyerusalem Shello Adelo, Ebrahim Abdela Siraj, Gizachew Kassahun Bizuneh, Betelhem Anteneh Adamu, Dawit Kumilachew Yimenu
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Background:Effective asthma management requires a multidisciplinary approach that includes; the physician, the patient, and the patient’s family.Objectives:The current study aimed to assess the roles played by community pharmacists toward asthma control together with the barriers hindering their practice and possible strategies to overcome those barriers.Methods:A multi-centered cross-sectional study was conducted. Data was collected using a structured, self-administered questionnaire adapted from previously conducted studies and customized to fit with the current study setup. The collected data was cleaned, coded, and entered into Statistical Package for Social Sciences (SPSS) version 21 for analysis. Descriptive analysis of the collected data was conducted and the results were presented using frequency tables and graphs.Results:A total of 122 community pharmacy professionals; 63 from Gondar, 26 from Bahir Dar, 15 from Debre Markos, 14 from Woldia, and 4 from Debre birhan participated in the study. About 96 (78.7%) of the participants reported that they teach their patients the basic facts about asthma. More than two-thirds of the participants 85 (69.7%) also reported that they were able to identify and manage the triggering factors of asthma for their patients. Lack of pharmacist time was reported by 78 (63.9%) of the study participants as a major reason for the inadequacy of the counseling service provided.Conclusion:It appears evident that there is a need for continuing professional education and pharmacists to receive additional training to improve their ability to go beyond identifying a problem and suggesting therapeutic options.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-08-28T11:39:28Z
      DOI: 10.1177/1479973120952679
      Issue No: Vol. 17 (2020)
  • Home-based or remote exercise testing in chronic respiratory disease,
           during the COVID-19 pandemic and beyond: A rapid review
    • Authors: Anne E Holland, Carla Malaguti, Mariana Hoffman, Aroub Lahham, Angela T Burge, Leona Dowman, Anthony K May, Janet Bondarenko, Marnie Graco, Gabriella Tikellis, Joanna YT Lee, Narelle S Cox
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Objectives:To identify exercise tests that are suitable for home-based or remote administration in people with chronic lung disease.Methods:Rapid review of studies that reported home-based or remote administration of an exercise test in people with chronic lung disease, and studies reporting their clinimetric (measurement) properties.Results:84 studies were included. Tests used at home were the 6-minute walk test (6MWT, two studies), sit-to-stand tests (STS, five studies), Timed Up and Go (TUG, 4 studies) and step tests (two studies). Exercise tests administered remotely were the 6MWT (two studies) and step test (one study). Compared to centre-based testing the 6MWT distance was similar when performed outdoors but shorter when performed at home (two studies). The STS, TUG and step tests were feasible, reliable (intra-class correlation coefficients>0.80), valid (concurrent and known groups validity) and moderately responsive to pulmonary rehabilitation (medium effect sizes). These tests elicited less desaturation than the 6MWT, and validated methods to prescribe exercise were not reported.Discussion:The STS, step and TUG tests can be performed at home, but do not accurately document desaturation with walking or allow exercise prescription. Patients at risk of desaturation should be prioritised for centre-based exercise testing when this is available.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-08-25T01:29:35Z
      DOI: 10.1177/1479973120952418
      Issue No: Vol. 17 (2020)
  • Early home-based pulmonary rehabilitation following acute exacerbation of
           COPD: A feasibility study using an action research approach
    • Authors: Bruna Wageck, Narelle S Cox, Janet Bondarenko, Monique Corbett, Amanda Nichols, Rosemary Moore, Anne E Holland
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Objective:Pulmonary rehabilitation (PR) improves function, reduces symptoms and decreases healthcare usage in people with chronic obstructive pulmonary disease (COPD) following an acute exacerbation (AECOPD). However, rehabilitation uptake rates are low. This study aimed to address barriers to uptake and completion of PR following AECOPD.Methods:An action research approach was used to reflect on study feasibility, and to plan and implement an improved protocol. Phase I tested the feasibility of home-based PR started early after AECOPD. Phase II used qualitative interviews to identified potential barriers to program uptake. Phase III re-tested the program with changes to recruitment and assessment strategies.Results:Phase I: From 97 screened patients, 26 were eligible and 10 (38%) started home-based PR. Eight participants undertook ≥70% of PR sessions, achieving clinically meaningful improvement in 6-minute walk distance (mean (SD) change 76 (60) m) and chronic respiratory disease questionnaire total score (15 (21) units). Phase II: Potential barriers to uptake of home-based PR included access issues, confidence to exercise, and lack of information about PR benefits. Phase III: From 77 screened patients, 23 were eligible and 5 (22%) started the program.Discussion:Home-based PR improved clinical outcomes, but program eligibility and uptake remain challenging. Efforts should be made to ensure PR program eligibility criteria are broad enough to accommodate patient needs, and new ways of engaging patients are needed to improve PR uptake after AECOPD.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-08-20T11:55:20Z
      DOI: 10.1177/1479973120949207
      Issue No: Vol. 17 (2020)
  • The prevalence of sleep-disordered breathing in Northwest Russia: The
           ARKHsleep study
    • Authors: Anna Khokhrina, Elena Andreeva, Jean-Marie Degryse
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Sleep-disordered breathing (SDB) is a chronic condition characterized by repeated breathing pauses during sleep. The reported prevalence of SDB in the general population has increased over time. Furthermore, in the literature, a distinction is made between SDB, obstructive sleep apnea (OSA), and “OSA syndrome” (OSAS). Patients with SDB are at increased risk of comorbid cardiovascular diseases (CVDs). The aim of the ARKHsleep study was to assess the prevalence of SDB in general and of OSA and OSAS in particular. A total of 1050 participants aged 30–70 years, who were randomly selected from a population register, were evaluated for the probability of SDB using the Epworth Sleepiness Scale score and body mass index. Sleep was recorded for one night via home sleep apnea testing (Somnolter®). Medical conditions were determined from medical records. Additional data included background characteristics, anthropometric variables, blood pressure, and scores from four questionnaires. The survey sample consisted of 41.2% males and had a mean age of 53.1 ± 11.3 years. The prevalence of mild-to-severe, moderate-to-severe, and severe SDB was 48.9% [45.8–51.9], 18.1% [15.9–20.6], and 4.5% [3.2–5.8], respectively. Individuals reporting snoring or breathing pauses had a higher severity of SDB than individuals free of symptoms. The ARKHsleep study revealed a high burden of both SDB and CVD; however, more large-scale cohort studies and intervention studies are needed to better understand whether the early recognition and treatment of mild SDB with or without symptoms will improve cardiovascular prognosis and/or quality of life.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-07-15T11:15:15Z
      DOI: 10.1177/1479973120928103
      Issue No: Vol. 17 (2020)
  • Digital habits of PR service-users: Implications for home-based
           interventions during the COVID-19 pandemic
    • Authors: Oliver Polgar, Maha Aljishi, Ruth E Barker, Suhani Patel, Jessica A Walsh, Samantha SC Kon, William DC Man, Claire M Nolan
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Remote models of pulmonary rehabilitation (PR) are vital with suspension of face-to-face activity during the COVID-19 pandemic. We surveyed digital access and behaviours and PR delivery preferences of current PR service users. There was significant heterogeneity in access to and confidence in using the Internet with 31% having never previously accessed the Internet, 48% confident using the Internet and 29% reporting no interest in accessing any component of PR through a Web-based app. These data have implications for the remote delivery of PR during the COVID-19 pandemic and raise questions about the current readiness of service users to adopt Web-based delivered models of PR.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-06-30T12:25:58Z
      DOI: 10.1177/1479973120936685
      Issue No: Vol. 17 (2020)
  • Anxiety and depression in bronchiectasis: Response to pulmonary
           rehabilitation and minimal clinically important difference of the Hospital
           Anxiety and Depression Scale
    • Authors: Stephanie C Wynne, Suhani Patel, Ruth E Barker, Sarah E Jones, Jessica A Walsh, Samantha SC Kon, Julius Cairn, Michael R Loebinger, Robert Wilson, William D-C Man, Claire M Nolan
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      The aims of the study were to evaluate the responsiveness of Hospital Anxiety and Depression Scale-Anxiety (HADS-A) subscale and HADS-Depression (HADS-D) subscale to pulmonary rehabilitation (PR) in patients with bronchiectasis compared to a matched group of patients with chronic obstructive pulmonary disease (COPD) and provide estimates of the minimal clinically important difference (MCID) of HADS-A and HADS-D in bronchiectasis. Patients with bronchiectasis and at least mild anxiety or depression (HADS-A ≥ 8 or/and HADS-D ≥ 8), as well as a propensity score-matched control group of patients with COPD, underwent an 8-week outpatient PR programme (two supervised sessions per week). Within- and between-group changes were calculated in response to PR. Anchor- and distribution-based methods were used to estimate the MCID. HADS-A and HADS-D improved in response to PR in both patients with bronchiectasis and those with COPD (median (25th, 75th centile)/mean (95% confidence interval) change: HADS-A change: bronchiectasis −2 (−5, 0), COPD −2 (−4, 0); p = 0.43 and HADS-D change: bronchiectasis −2 (−2 to −1), COPD −2 (−3 to −2); p = 0.16). Using 26 estimates, the MCID for HADS-A and HADS-D was −2 points. HADS-A and HADS-D are responsive to PR in patients with bronchiectasis and symptoms of mood disorder, with an MCID estimate of −2 points.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-06-17T06:59:35Z
      DOI: 10.1177/1479973120933292
      Issue No: Vol. 17 (2020)
  • Editorial on paper: The prevalence of sleep-disordered breathing in
           Northwest Russia – A problem worth knowing about'
    • Authors: Chris Turnbull
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.

      Citation: Chronic Respiratory Disease
      PubDate: 2020-06-09T11:22:37Z
      DOI: 10.1177/1479973120931863
      Issue No: Vol. 17 (2020)
  • Lung cancer resection and postoperative outcomes in COPD: A single-center
    • Authors: Emma Roy, Justine Rheault, Marc-Antoine Pigeon, Paula Antonia Ugalde, Christine Racine, Serge Simard, Gabriel Chouinard, Alexandre Lippens, Yves Lacasse, François Maltais
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Chronic obstructive pulmonary disease (COPD) increases postoperative morbidity and is associated with diminished long-term survival after lung cancer resection. Whether this is also true for mild-to-moderate COPD is uncertain. We conducted a retrospective analysis of all the patients who underwent lung cancer surgery between 2002 and 2012 in a university-affiliated hospital. The severity of airflow limitation was stratified according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) from stage 1 to 4. Data from 1456 cases of lung cancer surgery were reviewed and 1126 patients were included in the study: 672 (59.7%) patients had COPD (GOLD 1, n = 340; GOLD 2, n = 282; GOLD 3, n = 50) and 454 patients had a normal spirometry (controls). Following lung cancer resection, patients with COPD had a higher rate of postoperative morbidities of any kind (p < 0.0001), in particular, pneumonia (7.0% vs. 3.7%; p = 0.0251) and prolonged air leak (17.0% vs. 8.2%; p < 0.0001) than controls. In-hospital mortality was increased in GOLD 3 COPD but the incidence of other postoperative complications was not influenced by COPD severity. Neither COPD nor its severity influenced long-term survival in this population. To conclude, patients with COPD undergoing lung cancer surgery were at higher risk of postoperative complications than patients with normal respiratory function but the procedure was considered safe. The presence of COPD itself did not influence long-term survival. The results of our study apply mainly to patients with a GOLD 1 and 2 COPD since only a small number of patients with GOLD 3 COPD were involved.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-05-29T11:05:57Z
      DOI: 10.1177/1479973120925430
      Issue No: Vol. 17 (2020)
  • Validity of balance and mobility screening tests for assessing fall risk
           in COPD
    • Authors: Rachel McLay, Renata Noce Kirkwood, Ayse Kuspinar, Julie Richardson, Joshua Wald, Natya Raghavan, Cindy Ellerton, Stewart Pugsley, Marla K Beauchamp
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      People with chronic obstructive pulmonary disease (COPD) have balance impairments and an increased risk of falls. The psychometric properties of short balance tests to inform fall risk assessment in COPD are unknown. Our objective was to determine the validity (concurrent, convergent, and known-groups) of short balance and mobility tests for fall risk screening. Participants with COPD aged ≥ 60 years attended a single assessment. Correlation coefficients described the relationships between the Brief Balance Evaluation Systems Test (Brief BESTest), Single-Leg Stance (SLS), Timed Up and Go (TUG), and Timed Up and Go Dual-Task (TUG-DT) tests, with the comprehensive Berg Balance Scale (BBS), chair-stand test, and measures of exercise tolerance, functional limitation, disability, and prognosis. Independent t-tests or Mann–Whitney U tests were used to examine differences between groups with respect to fall risk. Receiver operating characteristic curves examined the ability of the screening tests to identify individuals with previous falls. A total of 86 patients with COPD completed the study (72.9 ± 6.8 years; forced expiratory volume in 1 second: 47.3 ± 20.3% predicted). The Brief BESTest identified individuals who reported a previous fall (area under the curve (AUC) = 0.715, p = 0.001), and the SLS showed borderline acceptable accuracy in identifying individuals with a fall history (AUC = 0.684, p = 0.004). The strongest correlations were found for the Brief BESTest and SLS with the BBS (r = 0.80 and r = 0.72, respectively) and between the TUG and TUG-DT with the chair-stands test (r = 0.73 and r = 0.70, respectively). The Brief BESTest and SLS show the most promise as balance screening tools for fall risk assessment in older adults with COPD. These tests should be further evaluated prospectively.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-05-11T11:49:59Z
      DOI: 10.1177/1479973120922538
      Issue No: Vol. 17 (2020)
  • Smoking status affects clinical characteristics and disease course of
           acute exacerbation of chronic obstructive pulmonary disease: A
           prospectively observational study
    • Authors: Xiaolong Li, Zhen Wu, Mingyue Xue, Wei Du
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Existing studies primarily explored chronic obstructive pulmonary disease (COPD) in smokers, whereas the clinical characteristics and the disease course of passive or nonsmokers have been rarely described. In the present study, patients hospitalized and diagnosed as acute exacerbation of COPD (AECOPD) were recruited and followed up until being discharged. Clinical and laboratory indicators were ascertained and delved into. A total of 100 patients were covered, namely, 52 active smokers, 34 passive smokers, and 14 nonsmokers. As revealed from the results here, passive or nonsmokers developed less severe dyspnea (patients with modified Medical Research Council scale (mMRC)
      Citation: Chronic Respiratory Disease
      PubDate: 2020-03-27T10:27:44Z
      DOI: 10.1177/1479973120916184
      Issue No: Vol. 17 (2020)
  • Acute exacerbations of chronic respiratory disease: Progress and
    • Authors: Christian R Osadnik
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.

      Citation: Chronic Respiratory Disease
      PubDate: 2020-03-20T01:28:10Z
      DOI: 10.1177/1479973120914459
      Issue No: Vol. 17 (2020)
  • Physical exercise during acute exacerbations of chronic obstructive
           pulmonary disease: Australian physiotherapy practice
    • Authors: Jessica S DeGaris, Christian R Osadnik
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Evidence supports an important role for pulmonary rehabilitation (PR) after acute exacerbations of chronic obstructive pulmonary disease (AECOPD); however, the role of physical exercise during hospitalisation is less clear. This study evaluated Australian physiotherapy practice and clinical perspectives regarding exercise and physical activity for patients with AECOPD. A national survey of 123 Australian public hospitals was conducted from 2016 to 2017 using a purpose-designed survey measuring self-reported physical exercise prescription, objective measure use, referral patterns and factors influencing service delivery. The response rate was 72% (88 hospitals; 176 physiotherapists). Most physiotherapists (92%) prescribed physical exercise frequently for patients with AECOPD and perceived their role to be important (81%). The most commonly prescribed modalities were ground walking (94%), sit-to-stand (89%) and non-equipment-based lower limb strengthening (79%). Only 32% of respondents offered physiotherapy evaluation during post-discharge outpatient clinic appointments at their hospital. While 71% of respondents indicated they frequently referred patients to PR after AECOPD, rates were significantly higher in those with more cardiorespiratory experience (82%) than those with less experience (66%; p = 0.026). Australian physiotherapists frequently prescribe simple physical exercise modalities for patients with AECOPD. PR referral rates appear influenced by clinician experience, which may need consideration in future remedial strategies.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-03-17T01:19:54Z
      DOI: 10.1177/1479973120912821
      Issue No: Vol. 17 (2020)
  • Monocyte count and the risk for acute exacerbation of fibrosing
           interstitial lung disease: A retrospective cohort study

         This is an Open Access Article Open Access Article

    • Authors: Kodai Kawamura, Kazuya Ichikado, Keisuke Anan, Yuko Yasuda, Yuko Sekido, Moritaka Suga, Hidenori Ichiyasu, Takuro Sakagami
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Recent studies have suggested that an increased peripheral monocyte count predicts a poor outcome in fibrosing interstitial lung disease (ILD). However, the association between an increased monocyte count and acute exacerbations (AEs) of fibrosing ILD remains to be elucidated. Our retrospective cohort study aimed to assess the impact of peripheral monocyte count on AEs of fibrosing ILD. We analyzed the electronic medical records of 122 consecutive patients with fibrosing ILD and no prior history of an AE, who were treated with anti-fibrotic agents from August 2015 to December 2018. We determined their peripheral monocyte counts at anti-fibrotic agent initiation and performed univariate and multivariate Cox regression analyses of time-to-first AE after anti-fibrotic agent initiation to assess the impact of monocyte count on AEs of fibrosing ILD. Twenty-six patients developed an AE during the follow-up period, and there was an increased monocyte count at anti-fibrotic agent initiation in these patients compared to those who did not develop an AE. There was also a significantly shorter time-to-first AE of fibrosing ILD in patients with a higher absolute monocyte count. Subgroup analyses indicated similar results regardless of the idiopathic pulmonary fibrosis diagnoses. This association was independently significant after adjusting for the severity of the fibrosing ILD. Using our results, we developed a simple scoring system consisting of two factors—monocyte count (380 µL−1) and ILD-gender, age, physiology score (4 points). Our findings suggest that the absolute monocyte count is an independent significant risk factor for AE in patients with fibrosing ILD. Our simple scoring system may be a predictor for AEs of fibrosing ILD, although further studies are needed to verify our findings.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-03-06T11:14:51Z
      DOI: 10.1177/1479973120909840
      Issue No: Vol. 17 (2020)
  • Nutritional supplementation during pulmonary rehabilitation in COPD: Do

         This is an Open Access Article Open Access Article

    • Authors: Bram van den Borst
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.

      Citation: Chronic Respiratory Disease
      PubDate: 2020-02-24T12:00:08Z
      DOI: 10.1177/1479973120904954
      Issue No: Vol. 17 (2020)
  • Nutritional supplementation during pulmonary rehabilitation in COPD: A
           systematic review

         This is an Open Access Article Open Access Article

    • Authors: Abdulelah M Aldhahir, Ahmed M Al Rajeh, Yousef S Aldabayan, Salifu Drammeh, Vanitha Subbu, Jaber S Alqahtani, John R Hurst, Swapna Mandal
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Uptake of nutritional supplementation during pulmonary rehabilitation (PR) for people with chronic obstructive pulmonary disease (COPD) has been limited by an absence of rigorous evidence-based studies supporting use. The objective was to report and summarise the current evidence supporting the use of nutritional supplementation to improve outcomes during PR in stable COPD patients. A systematic search was conducted up to 7 August 2019 (registration number CRD42018089142). The preferred reporting items for systematic reviews and meta-analyses guidelines were used. Six databases were included: Medical Literature Analysis and Retrieval System Online or MEDLARS Online, Allied and Complementary Medicine Database, the Cochrane Database of Systematic Reviews, Excerpta Medica dataBASE, Cumulative Index of Nursing and Allied Health Literature and Web of Science. This systematic search generated 580 initial matches, of which 22 studies (917 COPD participants) met the pre-specified criteria and were included. Sixteen of 19 studies that used nutritional supplements in addition to PR did not show additional benefit compared to PR alone when measuring exercise capacity. Nutritional supplements significantly increased body weight in 7 of 11 studies. Body mass index increased significantly in two of six studies. Handgrip strength did not improve, while quadriceps muscle strength significantly improved in 3 of 11 studies. Four of eight studies showed a significant improvement in inspiratory muscle function. Only 2 of 14 studies demonstrated a significant improvement in quality of life with supplementation in addition to PR. There remains insufficient evidence on the effect of nutritional supplementation on improving outcomes during PR in patients with COPD due to heterogeneity in supplements, outcome measures and PR programmes. Therefore, controversy remains and further research is needed.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-02-14T02:56:39Z
      DOI: 10.1177/1479973120904953
      Issue No: Vol. 17 (2020)
  • Use of 3-D navigation to target the site of autologous blood installation
           for lung volume reduction in bullous emphysema

         This is an Open Access Article Open Access Article

    • Authors: Juergen Hetzel, Michael Boeckeler, Richard A Lewis, Marius Horger, Maik Haentschel
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Bronchoscopic lung volume reduction (BLVR) using intrabullous autologous blood instillation has been reported in single cases where other techniques are not possible. We present the use of three-dimensional navigation to instill autologous blood into emphysematous bullae for BLVR. A 62-year-old man presented with increasing dyspnea, due to emphysema with a conglomerate of giant bullae with two particularly large bullae. Surgical treatment was refused, so bronchoscopic autologous blood instillation into the bronchial segment leading to the large bullae was attempted, but was unsuccessful; blood failed to penetrate into the bullous cavity. Dyspnea worsened over the following year. We therefore performed another bronchoscopy and punctured a large bulla with a needle and created a tunnel from the central airways. Puncture position and direction were determined using a prototype of an electromagnetic navigation system. Under fluoroscopic guidance, a catheter was placed via the tunnel into the bulla and blood was instilled. This resulted in an almost complete shrinkage of the bullae, reduction of residual volume, and marked improvement in dyspnea within 4 months. To our knowledge, this is the first reported case of successful BLVR by navigated bronchoscopy with transbronchial puncture, dilatation, and autologous blood instillation into a giant bulla.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-02-13T01:33:52Z
      DOI: 10.1177/1479973120903556
      Issue No: Vol. 17 (2020)
  • Reviewer’s List
         This is an Open Access Article Open Access Article

    • Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.

      Citation: Chronic Respiratory Disease
      PubDate: 2020-02-07T02:36:10Z
      DOI: 10.1177/1479973120904532
      Issue No: Vol. 17 (2020)
  • Hospitalization rates among patients with cystic fibrosis using pancreatic
           enzyme replacement therapy

         This is an Open Access Article Open Access Article

    • Authors: Bruce C. Trapnell, Su Chen, Rupal Khurmi, Amit Bodhani, Mudra Kapoor, Mark Haupt
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      We investigated the relationship between self-reported adherence to pancreatic enzyme replacement therapy (PERT), nutritional status, and all-cause hospitalization in cystic fibrosis (CF) patients with a record of PERT use. Association of self-reported annual PERT use rate (adherence) with annual hospital admission rate (HAR) and annual total hospital nights (THNs) were analyzed for 5301 children (2000–2012) and 13,989 adults (2000–2013) from the CF Foundation Patient Registry. Multivariate linear regression was used to determine the association of HAR and THN with mean annual PERT use rate, cumulative PERT use rate, mean body mass index (BMI) (adult) or BMI percentile (pediatric), age, and sex. The median annual PERT use rate was 87% in children and 80% in adults. Statistically, higher annual PERT use, longer cumulative PERT, and higher BMI percentile (children) or BMI (adults) were significantly (p < 0.0001) associated with lower annual HAR and fewer annual THN in children and adults. Female sex was associated with higher annual HAR and more annual THN in children and adults (p < 0.05). Results indicate self-reported adherence to PERT, increased BMI, and male sex were associated with fewer hospital admissions and annual hospital nights in CF patients.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-01-01T08:00:00Z
      DOI: 10.1177/1479973119900612
      Issue No: Vol. 17 (2020)
  • Device use errors with soft mist inhalers: A global systematic literature
           review and meta-analysis

         This is an Open Access Article Open Access Article

    • Authors: Maryam Navaie, Carole Dembek, Soojin Cho-Reyes, Karen Yeh, Bartolome R Celli
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Inhaled bronchodilators are the cornerstone of treatment for chronic obstructive pulmonary disease (COPD). Soft mist inhalers (SMIs) are devices that deliver bronchodilators. Although correct device use is paramount to successful medication delivery, patient errors are common. This global systematic literature review and meta-analysis examined device use errors with SMIs among patients with obstructive lung diseases. PubMed, EMBASE, PsycINFO, Cochrane, and Google Scholar were searched to identify studies published between 2010 and 2019 that met the following inclusion criteria: (a) English language; (b) a diagnosis of COPD, bronchitis, or emphysema; and (c) reported device use errors among adults receiving long-acting bronchodilator treatment with Respimat® SMI (i.e. Spiriva®, Stiolto®, Spiolto®, and Striverdi®). Descriptive statistics examined sociodemographics, clinical characteristics, and device use errors. Meta-analysis techniques were employed with random-effects models to generate pooled mean effect sizes and 95% confidence intervals (CIs) for overall and step-by-step errors. The I 2 statistic measured heterogeneity. Twelve studies (n = 1288 patients) were included in this meta-analysis. Eighty-eight percent of patients had COPD, and most had moderate/very severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease spirometric stages II to IV). Aggregate results revealed that 58.9% (95% CI: 42.4–75.5; I 2 = 92.8%) of patients made ≥1 device use errors. Among 11 studies with step-by-step data, the most common errors were failure to (1) exhale completely and away from the device (47.8% (95% CI: 33.6–62.0)); (2) hold breath for up to 10 seconds (30.6% (95% CI: 17.5–43.7)); (3) take a slow, deep breath while pressing the dose release button (27.9% (95% CI: 14.5–41.2)); (4) hold the inhaler upright (22.6% (95% CI: 6.2–39.0)); and (5) turn the base toward the arrows until it clicked (17.6% (95% CI: 3.0–32.2)). Device use errors occurred in about 6 of 10 patients who used SMIs. An individualized approach to inhalation device selection and ongoing training and monitoring of device use are important in optimizing bronchodilator treatment.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-01-01T08:00:00Z
      DOI: 10.1177/1479973119901234
      Issue No: Vol. 17 (2020)
  • Models of care across the continuum of exacerbations for patients with
           chronic obstructive pulmonary disease

         This is an Open Access Article Open Access Article

    • Authors: Jean Bourbeau, Carlos Echevarria
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality, and treatments require a multidisciplinary approach to address patient needs. This review considers different models of care across the continuum of exacerbations (1) chronic care and self-management interventions with the action plan, (2) domiciliary care for severe exacerbation and the impact on readmission prevention and (3) the discharge care bundle for management beyond the acute exacerbation episode. Self-management strategies include written action plans and coaching with patient and family support. Self-management interventions facilitate the delivery of good care, can reduce exacerbations associated with admission, be cost-effective and improve quality of life. Hospitalization as a complication of exacerbation is not always unavoidable. Domiciliary care has been proposed as a solution to replace part, and perhaps even all, of the patient’s in-hospital stay, and to reduce hospital bed days, readmission rates and costs; low-risk patients can be identified using risk stratification tools. A COPD discharge bundle is another potentially important approach that can be considered to improve the management of COPD exacerbations complicated by hospital admission; it comprised treatments that have demonstrated efficacy, such as smoking cessation, personalized pharmacotherapy and non-pharmacotherapy such as pulmonary rehabilitation. COPD bundles may also improve the transition of care from the hospital to the community following exacerbation and may reduce readmission rates. Future models of care should be personalized – providing patient education aiming at behaviour changes, identifying and treating co-morbidities, and including outcomes that measure quality of care rather than focusing only on readmission quantity within 30 days.
      Citation: Chronic Respiratory Disease
      PubDate: 2020-01-01T08:00:00Z
      DOI: 10.1177/1479973119895457
      Issue No: Vol. 17 (2020)
  • Pragmatic randomised controlled trial of a personalised intervention for
           carers of people requiring home oxygen therapy

         This is an Open Access Article Open Access Article

    • Authors: Peter Frith, Ruth Sladek, Richard Woodman, Tanja Effing, Sandra Bradley, Suzanne van Asten, Tina Jones, Khin Hnin, Mary Luszcz, Paul Cafarella, Simon Eckermann, Debra Rowett, Paddy A Phillips
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.
      We used a pragmatic randomised controlled trial to evaluate a behavioural change strategy targeting carers of chronically hypoxaemic patients using long-term home oxygen therapy. Intervention group carers participated in personalised educational sessions focusing on motivating carers to take actions to assist patients. All patients received usual care. Effectiveness was measured through a composite event of patient survival to hospitalisation, residential care admission or death to 12 months. Secondary outcomes at baseline, 3, 6 and 12 months included carer and patient emotional and physical well-being. No difference between intervention (n = 100) and control (n = 97) patients was found for the composite outcome (hazard ratio (HR) 1.22, 95% confidence interval (CI) = 0.89, 1.68; p = 0.22). Improved fatigue, mastery, vitality and general health occurred in intervention group patients (all p values < 0.05). No benefits were seen in carer outcomes. Mortality was significantly higher in intervention patients (HR = 2.01, 95% CI = 1.00, 4.14; p = 0.05; adjusted for Australia-modified Karnofsky Performance Status), with a significant diagnosis–intervention interaction (p = 0.028) showing higher mortality in patients with COPD (HR 4.26; 95% CI = 1.60, 11.35) but not those with interstitial lung disease (HR 0.83; 95% CI = 0.28, 2.46). No difference was detected in the primary outcome, but patient mortality was higher when carers had received the intervention, especially in the most disabled patients. Trials examining behavioural change interventions in severe disease should stratify for functionality, and both risks and benefits should be independently monitored. Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12607000177459).
      Citation: Chronic Respiratory Disease
      PubDate: 2020-01-01T08:00:00Z
      DOI: 10.1177/1479973119897277
      Issue No: Vol. 17 (2020)
  • Interventional lifestyle and self-management trials: A double-edged sword.
           Is it time to mandate formal data and safety monitoring'

         This is an Open Access Article Open Access Article

    • Authors: Neil J Greening, Tom JC Ward
      Abstract: Chronic Respiratory Disease, Volume 17, Issue , January-December 2020.

      Citation: Chronic Respiratory Disease
      PubDate: 2020-01-01T08:00:00Z
      DOI: 10.1177/1479973119897280
      Issue No: Vol. 17 (2020)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-